<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646736</url>
  </required_header>
  <id_info>
    <org_study_id>T2WILN</org_study_id>
    <nct_id>NCT01646736</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Glucocorticosteroid Combined With Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of Patients With Lupus Nephritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the clinical efficacy and safety profile of glucocorticosteroid combined with oral
      T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the treatment of
      patients with lupus nephritis. Open-labeled, randomized, prospective multi-center clinical
      trial. Observation period of 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Response</measure>
    <time_frame>24 weeks.</time_frame>
    <description>The proportion of patients achieving Complete Response (CR) and Partial Response(PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in glomerular filtration rate(GFR) from baseline to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Albumin Level</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in serum albumin level from baseline to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in complement components from baseline to week 24, including: CH50(total complement activity), C3 and C4 level measured by nephelometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-dsDNA</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in anti-dsDNA antibody titers from baseline to week 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Nephritis, Lupus</condition>
  <arm_group>
    <arm_group_label>GC+CYC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were treated with Glucocorticosteroid and Cyclophosphamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC+T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with Glucocorticosteroid and oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tripterygium wilfordii Hook F</intervention_name>
    <description>Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.</description>
    <arm_group_label>GC+T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 1.0 intravenous every month.</description>
    <arm_group_label>GC+CYC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC</intervention_name>
    <description>Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.</description>
    <arm_group_label>GC+CYC</arm_group_label>
    <arm_group_label>GC+T2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years with informed consent

          -  SLE defined by meeting 4 or more ACR classification criteria

          -  Biopsy-proven active proliferative lupus glomerulonephritis ISN classification Class
             III or IV

          -  Active renal disease

        Exclusion Criteria:

          -  Pregnant, lactating or further fertility requirements

          -  Serum creatinine &gt; 3 mg/dL

          -  Serum ALT or AST &gt; 3 times upper limit of normal

          -  Severe, progressive renal, hepatic, hematological, gastrointestinal, pulmonary,
             cardiovascular, neurological, endocrine or cerebral disease

          -  Previous treated with cyclophosphamide or T2.

          -  Not discontinuing MMF, azathioprine, leflunomide, methotrexate, calcineurin inhibitor
             before 1 month of randomization.

          -  Active or chronic infection, including HIV, HCV, HBV, tuberculosis

          -  Patient with malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengchun Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Chen, MD</last_name>
    <phone>+861069158797</phone>
    <email>chenhua@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deptment of Rheumatology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengchun Zhang, MD</last_name>
      <phone>861069158792</phone>
      <email>ZhangFCcra@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Fengchun Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Fengchun Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lupus Nephritis</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Tripterygium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

